Table 1.
Baseline subject characteristics.
| Whole group | No acetazolamide | Acetazolamide | P | |
|---|---|---|---|---|
| Age (years) | 36.8 ± 10.6 | 35.7 ± 9.7 | 39.1 ± 11.5 | 0.019 |
| Gender, M (%) | 168 (70) | 94 (69) | 63 (69) | 0.92 |
| BMI (kg/m2) | 26.1 ± 4.2 | 25.6 ± 3.7 | 26.7 ± 4.7 | 0.07 |
| Body fat (%) | ||||
| Males | 16.5 ± 6.2 | 15.5 ± 6.0 | 17.9 ± 6.1 | 0.015 |
| Females | 26.3 ± 7.1 | 25.7 ± 7.3 | 27.5 ± 6.8 | 0.32 |
| Elevation of residence (last 3 months), no. (%) | 0.13 | |||
| <5,000 ft above sea level | 152 (64) | 78 (58) | 66 (73) | |
| 5,000–7,500 ft above sea level | 74 (31) | 49 (36) | 21 (23) | |
| 7,500–10,000 ft above sea level | 11 (5) | 7 (5) | 4 (4) | |
| >10,000 ft above sea level | 1 (0) | 1 (1) | 0 (0) | |
| Previous altitude exposure (≥10,000 ft), no. (%) | 213 (89) | 128 (94) | 75 (82) | 0.005 |
| Last time at an altitude ≥10,000 ft, no. (%) | ||||
| <2 weeks ago | 5 (2) | 4 (3) | 1 (1) | 0.027 |
| 2 to 4 weeks ago | 24 (11) | 20 (16) | 3 (4) | |
| >4 weeks ago | 184 (86) | 104 (81) | 71 (95) | |
| Previous altitude illness (among those with previous exposure), no. (%) | 0.006 | |||
| No problem | 84 (39) | 56 (44) | 23 (31) | |
| Mild problem | 112 (53) | 67 (52) | 40 (53) | |
| Moderate problem | 17 (8) | 5 (4) | 12 (16) | |
| Previously at south pole before, no. (%) | 110 (46) | 75 (56) | 32 (35) | 0.003 |